Search results
Results From The WOW.Com Content Network
The Food and Drug Administration announced a Class II recall for more than 7,000 bottles of an antidepressant due to a chemical. The recall was initiated earlier this month on Oct. 10.
Thousands of bottles of the medicine duloxetine are being recalled because they may contain a potentially cancer-causing agent.
Thousands of bottles of the antidepressant duloxetine, which is the generic version of Cymbalta, have been recalled due to the presence of a toxic chemical, according to a notice from the Food...
The US Food and Drug Administration (FDA) has announced a voluntary manufacturer-initiated recall of more than 7000 bottles of duloxetine delayed-release capsules due to unacceptable levels of a...
The FDA has recalled thousands of bottles of the antidepressant duloxetine, sold under brand name Cymbalta, due to the presence of a possibly cancer-causing chemical.
The product was recalled due to cgmp deviations: presence of nitrosamine drug substance related impurity (ndsri), n-nitroso-duloxetine, above the proposed interim limit.. The product was distributed nationwide and the recall is currently ongoing.
The FDA issued a recall notice for more than 7,000 bottles of duloxetine, a drug used to treat depression, anxiety, and nerve pain. The recalled lot may contain high levels of nitrosamines, a carcinogenic compound.
The recall, announced on October 10, affects only 20 mg Duloxetine Delayed-Release Capsules made by Towa Pharmaceutical Europe, targeting over 7,100 bottles with lot number 220128 and an...
Over 7,000 bottles of the antidepressant medication duloxetine, sold under the brand name Cymbalta, have been recalled, the FDA announced. The medication, produced by Towa Pharmaceutical Europe...
On October 23, 2024, the FDA announced a Class II recall for 7107 bottles of duloxetine (Cymbalta; Eli Lilly & Company) because it contained the presence of nitrosamine substance impurity, N-nitroso-duloxetine.